Joaquin Sanchez-Garcia
Overview
Explore the profile of Joaquin Sanchez-Garcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boluda B, Rodriguez-Veiga R, Sargas C, Ayala R, Larrayoz M, Chillon M, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075701
Background/objectives: This PETHEMA PCR-LMA study aimed to evaluate whether mutations detected by NGS (VAF cut-off of ≥5%) correlate with NPM1, FLT3-ITD, FLT3-TKD, IDH1, and IDH2 mutations detected using conventional PCR...
2.
Colmenares R, Alvarez N, Barragan E, Boluda B, Larrayoz M, Chillon M, et al.
Haematologica
. 2025 Feb;
PMID: 40013390
Not available.
3.
Serrano J, Martinez-Cuadron D, Gil C, Bernal T, Tormo M, Martinez-Sanchez P, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39956320
It is widely accepted that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the sole potentially curative option available for secondary acute myeloid leukemia (sAML). However, clinical factors impacting outcomes after...
4.
Diez-Campelo M, Lopez-Cadenas F, Xicoy B, Lumbreras E, Gonzalez T, Gonzalez M, et al.
Lancet Haematol
. 2024 Jul;
11(9):e659-e670.
PMID: 39033767
Background: Lenalidomide is the standard of care for patients who are transfusion dependent with chromosome 5q deletion (del[5q]) myelodysplastic syndromes. In the SintraREV trial, we aimed to investigate whether an...
5.
Labrador J, Martinez-Cuadron D, Boluda B, Serrano J, Gil C, Perez-Simon J, et al.
Cancer
. 2024 Jun;
130(20):3436-3451.
PMID: 38896056
Background: There are no studies assessing the evolution and patterns of genetic studies performed at diagnosis in acute myeloid leukemia (AML) patients. Such studies could help to identify potential gaps...
6.
Cordoba R, Sanchez-Garcia J, Domingo-Domenech E, Lopez Jimenez J, Martinez Pozo A, Carpio C, et al.
Expert Rev Hematol
. 2024 Feb;
17(1-3):95-100.
PMID: 38299464
Background: An accurate assessment of tumor viability after first-line treatment is critical for predicting treatment failure in peripheral T-cell lymphomas (PTCLs). F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) has been...
7.
Garcia-Sancho A, Rodriguez-Pinilla S, Domingo-Domenech E, Climent F, Sanchez-Garcia J, Lopez Jimenez J, et al.
Br J Haematol
. 2023 Jun;
203(2):182-193.
PMID: 37386897
Nodal peripheral T-cell lymphoma (PTCL) with a T follicular helper phenotype (PTCL-TFH) is a new type of PTCL. We aimed to define its clinical characteristics and prognosis compared to PTCL...
8.
Sargas C, Ayala R, Larrayoz M, Chillon M, Rodriguez-Arboli E, Bilbao C, et al.
Blood Cancer J
. 2023 May;
13(1):77.
PMID: 37173322
Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in...
9.
Sanchez-Garcia J, Serrano J, Prados de la Torre E, Serrano-Lopez J, Aparicio-Perez C, Barragan E, et al.
Expert Rev Hematol
. 2023 Mar;
16(4):277-287.
PMID: 36951195
Introduction: Acute myeloid leukemia (AML) is a heterogeneous disease currently including 12 entities defined by genetic findings with remarkable differences in prognosis and targeted therapies availability. Therefore, identification of genetic...
10.
Aparicio-Perez C, Prados de la Torre E, Sanchez-Garcia J, Martin-Calvo C, Martinez-Losada C, Casano-Sanchez J, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900222
Acute myeloid leukemia (AML) is a heterogeneous disease classified into three risk categories (favorable, intermediate and adverse) with significant differences in outcomes. Definitions of risk categories evolve overtime, incorporating advances...